Évolocumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Évolocumab" in French language version.

refsWebsite

Global rank French rank

3thelancet.com

2,393^rd place

506^th place

3nejm.org

2,374^th place

298^th place

3ahajournals.org

3,608^th place

659^th place

1sciencedirect.com

149^th place

80^th place

1onlinejacc.org

low place

2,587^th place

1oup.com

485^th place

416^th place

1jamanetwork.com

2,650^th place

689^th place

1europa.eu

68^th place

67^th place

1fda.gov

447^th place

1,409^th place

1leparisien.fr

233^rd place

16^th place

1vidal.fr

low place

910^th place

ahajournals.org

circ.ahajournals.org

(en) Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA, « Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial » Circulation, 2012;126:2408–2417.
(en) Koren MJ, Giugliano RP, Raal FJ et al. « Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial », Circulation, 2014;129:234-243.

ahajournals.org

O'Donoghue ML, Giugliano RP, Wiviott SD et al. Long-Term evolocumab in patients with established atherosclerotic cardiovascular disease, Circulation, 2022;146:1109–1119

europa.eu

ema.europa.eu

(en) « First-in-class treatment to lower cholesterol », sur ema.europa.eu, EMA, 22 mai 2015 (consulté le 31 août 2015).

fda.gov

(en) « FDA approves Repatha to treat certain patients with high cholesterol », sur fda.gov, FDA, 27 août 2015 (consulté le 31 août).

jamanetwork.com

jama.jamanetwork.com

Evolocumab (Repatha)—A second PCSK9 inhibitor to lower LDL-cholesterol, JAMA, 2015;314:2298-2299

leparisien.fr

De nouveaux anti-cholestérol coûteux réduisent le risque cardiovasculaire, Le Parisien, 17 mars 2017

nejm.org

Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 2017;376:1713-1722
N Engl J Med 2020; 383:1317-1327 DOI: 10.1056/NEJMoa2019910 https://www.nejm.org/doi/full/10.1056/NEJMoa2019910?query=TOC
(en) Sabatine MS, Giugliano RP, Wiviott SD et al. « Efficacy and safety of evolocumab in reducing lipids and cardiovascular events » N Engl J Med, 2015;372:1500-1509.

onlinejacc.org

content.onlinejacc.org

(en) Raal FJ, Giugliano RP, Sabatine MS et al. « Reduction in Lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials » J Am Coll Cardiol, 2014;63:1278-1288.

oup.com

academic.oup.com

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR, Controlled study of the effect of proprotein convertase subtilisin–kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics, Eur Heart J, 2018;39:2577–2585

sciencedirect.com

Nicholls SJ, Kataoka Y, Nissen SE et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction, JACC Cardiovasc Imaging, 2022;15:1308–1321

thelancet.com

(en) Koren MJ, Scott R, Kim JB et al. « Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study » Lancet, 2012;380:1995–2006.
(en) Giugliano RP, Desai NR, Kohli P et al. « Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study » Lancet, 2012;380:2007–2017.
Giugliano RP, Pedersen TR, Jeong-Gun Park J-G et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, Lancet, 2017;390:1962–1971

vidal.fr

Paitraud D, Hypercholestérolémie : REPATHA (evolocumab), nouvel anticorps monoclonal anti-PCSK9 sur le dite Vidal.fr